| scholarly article | Q13442814 |
| P50 | author | Gherardo Tapete | Q87101844 |
| P2093 | author name string | Giampaolo Bresci | |
| Rodolfo Sacco | |||
| Luca Giacomelli | |||
| Giuseppe Cabibbo | |||
| Natalia Simonetti | |||
| Veronica Natali | |||
| Lilia Biscaglia | |||
| Rossella Sellitri | |||
| Sara Melissari | |||
| P2860 | cites work | Transarterial radioembolization for hepatocellular carcinoma: a review | Q26738273 |
| EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 | ||
| Sorafenib in combination with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis | Q28072749 | ||
| Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives | Q28081783 | ||
| Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival | Q29616865 | ||
| Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. | Q34622672 | ||
| Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. | Q34714683 | ||
| Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. | Q35164855 | ||
| Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. | Q35658940 | ||
| Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study | Q36309974 | ||
| Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis | Q36371605 | ||
| Multimodal approaches to the treatment of hepatocellular carcinoma | Q37384682 | ||
| Single-Agent versus Combination Doxorubicin-Based Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Single-Blind, Randomized, Phase II Trial. | Q53029491 | ||
| TACE with or without systemic therapy? | Q83609274 | ||
| Intermediate hepatocellular carcinoma: current treatments and future perspectives | Q38110203 | ||
| Transarterial chemoembolization and sorafenib in hepatocellular carcinoma | Q38213650 | ||
| Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results | Q38526335 | ||
| Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo | Q38541397 | ||
| Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. | Q38711169 | ||
| Combination of Transarterial Chemoembolization (TACE) and Radiofrequency Ablation (RFA) vs. Surgical Resection (SR) on Survival Outcome of Early Hepatocellular Carcinoma: A Meta-Analysis | Q38742400 | ||
| In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? | Q38984450 | ||
| A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma | Q39905453 | ||
| TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. | Q40129689 | ||
| Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. | Q44885846 | ||
| Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness | Q46821572 | ||
| Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma | Q48058236 | ||
| Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. | Q48092299 | ||
| The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial | Q48238287 | ||
| Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice? | Q48411584 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 105-110 | |
| P577 | publication date | 2017-07-27 | |
| P1433 | published in | Journal of hepatocellular carcinoma | Q27727369 |
| P1476 | title | Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review | |
| P478 | volume | 4 |
| Q61811584 | A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007-2015 |
| Q89442108 | Antitumor Efficacy of Huqizhengxiao (HQZX) Decoction Based on Inhibition of Telomerase Activity in Nude Mice of Hepatocarcinoma Xenograft |
| Q88542972 | Arsenic trioxide combined with transarterial chemoembolization for unresectable primary hepatic carcinoma: A systematic review and meta-analysis |
| Q92344068 | Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC) |
| Q47831501 | Drug-eluting bead transarterial chemoembolization in the treatment for unresectable soft tissue sarcoma refractory to systemic chemotherapy: a preliminary evaluation of efficacy and safety. |
| Q58869848 | IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies |
| Q93087682 | Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization |
| Q90614002 | Sarcopenia Is a Negative Prognostic Factor in Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatic Malignancies |
| Q90171775 | The Combination Strategy of Transarterial Chemoembolization and Radiofrequency Ablation or Microwave Ablation against Hepatocellular Carcinoma |
| Q92835198 | Time-series clustering of cytokine expression after transarterial chemoembolization in patients with hepatocellular carcinoma |
Search more.